

# Synthesis of D-Fructose-Based Bifunctional Primary Amine-Thiourea Organocatalysts and Their Applications in Asymmetric Reactions

Samson Lalhmangaihzualla <sup>1,2</sup>, Vanlalngaihawma Khiangte <sup>1,2</sup>, Zathang Laldinpuii <sup>1,2</sup>, Lal Nunnemi <sup>1,2</sup>, Joute Malsawmsanga <sup>1,2</sup>, Gospel Lallawmzuali <sup>1,3</sup>, Thanhming Liana <sup>1</sup>, Chhakchhuak Lalhriatpuia <sup>1</sup>, Zodinpuia Pachuau <sup>2</sup> and Khiangte Vanlaldinpuia <sup>1,\*</sup>

<sup>1</sup> Department of Chemistry, Pachhunga University College, Mizoram University, Aizawl 796001, Mizoram, India

<sup>2</sup> Department of Chemistry, Mizoram University, Tanhril, Aizawl 796004, Mizoram, India

<sup>3</sup> Department of Environmental Science, Mizoram University, Tanhril, Aizawl 796004, Mizoram, India

\* Correspondence: mapuiakhiangte@pucollege.edu.in

---

## Table of contents

Typical procedure for asymmetric Michael Addition reaction **8a–o**: Page 2–5

Typical procedure for the asymmetric Aldol reaction **9a–e**: Page 5–6

Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of the catalysts: Page 7–14.

Copies of HRMS data of the catalysts: Page 15–16.

Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of Michael adducts: Page 17–31.


Copies of HPLC data of enantioenriched and racemic data of compound **8a–o**: Page 32–46.

Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of Aldol adducts: Page 47–51.


Copies of HPLC data of enantioenriched and racemic data of compound **9a–e**: Page 52–56.

### Typical procedure for asymmetric Michael Addition reaction:


To a stirred solution of  $\beta$ -nitrostyrene (0.2 mmol) and ketone (3 equiv.) in dry dichloromethane (0.25 ml), 15 mol% saccharide-based amine-thiourea organocatalyst and benzoic acid were added. The reaction mixture was then stirred at room temperature for an appropriate reaction time, followed by concentration under vacuum. The reaction mixture was then subjected to purification by column chromatography using silica gel (60-120 mesh) with a hexane:EtOAc mixture as an eluent to obtain the desired product. The enantiomeric excess values of the product were determined by HPLC analysis on a chiral column using a mixture of n-hexane and iso-propanol as the mobile phase.




(*S*)-4-(4-bromophenyl)-5-nitropentan-2-one (**7a**): yield: 95% as yellow solid.  $[\alpha]_D^{25} = -12.1$  ( $c = 0.068$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=85/15, UV 220 nm, flow rate 1.0 ml/min,  $t_R$ =10.2 min (major, *S*),  $t_R$ =12.6 (minor, *R*), ee: >99%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.40-7.36 (m, 2H), 7.04-7.02 (m, 2H), 4.63-4.47 (m, 2H), 3.94-3.87 (m, 1H), 2.82 (d, 2H,  $J = 8$  Hz), 2.06 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  204.95, 137.88, 132.21, 131.57, 131.18, 129.15, 121.87, 79.09, 45.91, 38.47, 30.37 ppm.




(*S*)-4-(4-chlorophenyl)-5-nitropentan-2-one (**7b**): yield: 90% as yellow solid.  $[\alpha]_D^{25} = +5.9$  ( $c = 0.052$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=85/15, UV 220 nm, flow rate 1.0 ml/min,  $t_R$ =9.8 min (major, *S*),  $t_R$ =11.5 (minor, *R*) ee: 91%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.24-7.20 (m, 2H), 7.11-7.07 (m, 2H), 4.63-4.47 (m, 2H), 4.06-3.88 (m, 1H), 2.82 (d, 2H,  $J = 8$  Hz), 2.05 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  205.00, 137.36, 133.78, 130.86, 129.25, 128.82, 128.59, 79.18, 45.97, 38.41, 30.36 ppm.




(*S*)-5-nitro-4-(*p*-tolyl)pentan-2-one (**7c**): yield: 81% as white solid.  $[\alpha]_D^{25} = +1.2$  ( $c = 0.045$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=85/15, UV 220 nm, flow rate 1.0 ml/min,  $t_R$ =7.4 min (major, *S*),  $t_R$ =8.2 (minor, *R*) ee:85%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.20-7.07 (m, 4H), 4.69-4.54 (m, 2H), 4.00-3.93 (m, 1H), 2.89 (d, 2H,  $J = 8$  Hz), 2.31 (s, 3H), 2.10 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  204.56, 136.56, 134.75, 128.70, 127.91, 126.51, 126.21, 78.60, 45.18, 37.73, 29.34, 19.99 ppm.




(*S*)-4-(2-chlorophenyl)-5-nitropentan-2-one (**7d**): yield: 88% as yellow oil.  $[\alpha]_D^{25} = +6.8$  ( $c = 0.062$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=90/10, UV 210 nm, flow rate 1.0 ml/min,  $t_R$ =9.817 min (major, *S*),  $t_R$ =12.583 min (minor, *R*) ee:83%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.34-7.12 (m, 4H), 4.73-4.64 (m, 2H), 4.43-4.36 (m, 1H), 3.02-2.86 (m, 2H), 2.09 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  204.24, 134.97, 132.71, 129.41, 128.03, 127.40, 126.38, 76.41, 43.50, 34.78, 29.18 ppm.




(*S*)-4-(2-methoxyphenyl)-5-nitropentan-2-one (**7e**): yield: 94% as pale-yellow oil.  $[\alpha]_{\text{D}}^{25} = +15.3$  ( $c = 0.034$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=48/2, UV 205 nm, flow rate 0.5 ml/min,  $t_{\text{R}}=31.2$  min (major, *S*),  $t_{\text{R}}=32.7$  (minor, *R*) ee: 81%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.17-7.15 (m, 1H), 7.07-7.05 (m, 1H), 6.84-6.80 (m, 2H), 4.69-4.63 (m, 2H), 4.17-4.12 (m, 1H), 3.78 (s, 3H), 2.98-2.84 (m, 2H), 2.04 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  205.15, 156.09, 128.27, 127.97, 125.45, 119.88, 109.99, 76.84, 54.32, 43.51, 34.34, 29.18 ppm.




(*S*)-5-nitro-4-phenylpentane-2-one (**7f**): yield: 93% as white solid.  $[\alpha]_{\text{D}}^{25} = +6.9$  ( $c = 0.055$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=97/3, UV 220 nm, flow rate 1 ml/min,  $t_{\text{R}}=18.3$  min (major, *S*),  $t_{\text{R}}=21.4$  (minor, *R*) ee: 95%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.37-7.23 (m, 5H), 4.74-4.60 (m, 2H), 4.07-3.99 (m, 1H), 2.94 (d,  $J = 8$  Hz, 2H), 2.14 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  205.39, 138.82, 129.09, 127.92, 127.39, 79.46, 46.18, 39.05, 30.40 ppm.




(*S*)-3-(1-(4-chlorophenyl)-2-nitroethyl)pentane-2,4-dione (**7g**): yield: 80% as white solid.  $[\alpha]_{\text{D}}^{25} = +6.9$  ( $c = 0.055$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=80/20, UV 205 nm, flow rate 1 ml/min,  $t_{\text{R}}=8.2$  min (major, *S*),  $t_{\text{R}}=22.0$  (minor, *R*) ee: 84%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.32-7.29 (m, 2H), 7.15-7.11 (m, 2H), 4.65-4.58 (m, 2H), 4.34-4.20 (m, 2H), 2.30 (s, 3H), 1.97 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.38, 200.55, 134.58, 134.27, 133.22, 129.57, 129.33, 77.92, 70.56, 42.15, 30.41, 29.64 ppm.




(*S*)-3-(2-nitro-1-(p-tolyl)ethyl)pentane-2,4-dione (**7h**): yield: 73% as white solid.  $[\alpha]_{\text{D}}^{25} = +91.3$  ( $c = 0.066$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=90/10, UV 210 nm, flow rate 1 ml/min,  $t_{\text{R}}=10.0$  min (major, *S*),  $t_{\text{R}}=17.1$  (minor, *R*) ee: 81%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.13-7.05 (m, 4H), 4.64-4.56 (m, 2H), 4.35 (d, 1H,  $J = 8$  Hz), 4.23-4.17 (m, 1H), 2.30 (s, 3H), 2.29 (s, 3H), 1.94 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.88, 201.08, 138.38, 132.85, 130.01, 127.78, 78.38, 70.88, 42.47, 30.38, 29.41, 21.05 ppm.




(*S*)-3-(1-(4-bromophenyl)-2-nitroethyl)pentane-2,4-dione (**7i**): yield: 78% as pale-yellow solid.  $[\alpha]_{\text{D}}^{25} = +141.7$  ( $c = 0.068$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=85/15, UV 210 nm, flow rate 1 ml/min,  $t_{\text{R}}=10.6$  min (major, *S*),  $t_{\text{R}}=29.8$  (minor, *R*) ee: 81%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.48-7.45 (m, 2H), 7.09-7.05 (m, 2H), 4.65-4.58 (m, 2H), 4.32 (d, 1H,  $J = 12$  Hz), 4.24-4.18 (m, 1H), 2.30 (s, 3H), 1.98 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.40, 200.56, 135.11, 132.58, 129.68, 122.71, 77.87, 70.54, 42.22, 30.42, 29.64 ppm.




(*S*)-3-(1-(2-chlorophenyl)-2-nitroethyl)pentane-2,4-dione (**7j**): yield: 62% as pale-yellow solid.  $[\alpha]_{\text{D}}^{25} = +200.1$  ( $c = 0.048$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH= 49/1, UV 205 nm, flow rate 0.5 ml/min,  $t_{\text{R}}=33.9$  min (major, *S*),  $t_{\text{R}}=36.1$  (minor, *R*) ee: 76%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.38-7.07 (m, 4H), 4.79-4.75 (m, 1H), 4.70-4.65 (m, 1H), 4.61-4.52 (m, 2H), 2.23 (s, 3H), 1.97 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.89, 200.83, 133.78, 133.45, 130.67, 129.73, 129.04, 127.67, 77.33, 69.02, 38.86, 30.88, 28.43 ppm.




(*S*)-3-(1-(2-methoxyphenyl)-2-nitroethyl)pentane-2,4-dione (**7k**): yield: 52% as pale-yellow oil.  $[\alpha]_{\text{D}}^{25} = +196.8$  ( $c = 0.055$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH= 49/1, UV 210 nm, flow rate 0.5 ml/min,  $t_{\text{R}}=36.6$  min (major, *S*),  $t_{\text{R}}=40.0$  (minor, *R*) ee: 71%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.22-7.17 (m, 1H), 7.02-7.00 (m, 1H), 6.84-6.80 (m, 2H), 4.74-4.69 (m, 1H), 4.54-4.49 (m, 2H), 4.44-4.39 (m, 1H), 3.81 (s, 3H), 2.21 (s, 3H), 1.87 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  203.08, 202.27, 158.11, 139.57, 134.04, 131.20, 128.98, 79.57, 60.27, 52.90, 31.58, 30.60, 22.24 ppm.



(*S*)-3-(2-nitro-1-phenylethyl)pentane-2,4-dione (**7l**): yield: 81% as pale-yellow solid.  $[\alpha]_{\text{D}}^{25} = +173.1$  ( $c = 0.048$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=45/5, UV 210 nm, flow rate 0.5 ml/min,  $t_{\text{R}}=21.8$  min (major, *S*),  $t_{\text{R}}=29.5$  (minor, *R*) ee: 74%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.40-7.10 (m, 5H), 4.59-4.52 (m, 2H), 4.32-4.16 (m, 2H), 2.22 (s, 3H), 1.87 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.80, 201.03, 135.99, 129.35, 129.17, 128.88, 128.57, 127.94, 78.19, 42.80, 30.44, 29.55 ppm.




(*R*)-2-[(*S*)-1-(4-methylphenyl)-2-nitroethyl] cyclohexanone (**7m**): yield: 46% as yellow solid.  $[\alpha]_{\text{D}}^{25} = +13.1$  ( $c = 0.05$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=48/2, UV 254 nm, flow rate 0.5 ml/min, retention time: 25.0 min (major, *syn*), 29.7 min (minor, *anti*), 31.3 min (major, *anti*) 38.8 min (minor, *syn*).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.15-7.03 (m, 4H), 4.96-4.80 (m, 1H), 4.65-4.60 (m, 1H) 4.01-3.96 (m, 1H for *anti*), 3.77-3.71 (m, 1H for *syn*), 2.76-2.66 (m, 1H), 2.52-1.20 (m, 11H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  212.08 (*syn*), 210.58 (*anti*), 137.46, 137.22, 135.22, 134.60, 129.63, 129.45, 128.24, 128.01, 79.03, 53.82, 52.59, 43.59, 42.76, 42.74, 33.19, 30.03, 28.54, 27.36, 25.03, 25.01, 21.06 ppm.



(*S*)-2-[(*R*)-1-(4-bromophenyl)-2-nitroethyl] cyclohexanone (**7n**): yield: 55% as white solid. Chiralpak AD-H, hexane/*i*-PrOH=90/10, UV 254 nm, flow rate 1 ml/min, retention time: 11.9 min (minor, *syn*), 13.6 min (major, *anti*), 15.3 min (minor, *anti*) 18.7 min (major, *syn*).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.65-7.44 (m, 2H), 7.18-7.06 (m, 2H), 4.97-4.85 (m, 1H), 4.84-4.58 (m, 1H), 3.96-3.78 (m, 1H for *anti*), 3.77-3.73 (m, 1H for *syn*), 2.75-2.63 (m, 1H), 2.51-1.25 (m, 8H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  211.55 (*syn*), 210.30 (*anti*), 137.37,


136.86, 133.75, 132.10, 131.87, 130.23, 129.93, 128.51, 121.73, 78.52, 53.55, 52.35, 43.44, 42.90, 42.74, 33.17, 30.32, 28.44, 27.35, 25.07 ppm.




(*S*)-2-((*R*)-2-Nitro-1-phenylethyl)cyclohexan-1-one (**7o**): yield: 42% as white solid.  $[\alpha]_D^{25} = -6.1$  ( $c = 0.048$ ,  $\text{CHCl}_3$ ). Chiralpak AD-H, hexane/*i*-PrOH=90/10, UV 254 nm, flow rate 1 ml/min, retention time: 12.6 min (minor, *syn*), 14.5 min (minor, *anti*), 19.1 min (major, *anti*), 25.9 min (major, *syn*).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.57-7.09 (m, 5H), 4.89-4.74 (m, 1H), 4.59-4.53 (m, 1H), 3.96-3.72 (m, 1H for *anti*), 3.71-3.66 (m, 1H for *syn*), 2.69-2.58 (m, 1H), 2.44-1.11 (m, 8H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  212.00 (*syn*), 210.52 (*anti*), 128.95, 128.76, 128.50, 128.18, 127.79, 127.56, 78.90, 53.78, 52.55, 43.95, 43.08, 42.33, 33.22, 30.00, 28.54, 27.35, 25.04 ppm.

### Typical procedure for the asymmetric Aldol reaction:


A solution of 20 mol% of the saccharide-based amine-thiourea organocatalyst **6a**, 20 mol% of benzoic acid, aldehydes (0.2 mmol), and ketone (4 equiv.) in water (0.5 ml) was stirred at 0 °C. The reaction mixture was then concentrated under vacuum, followed by purification with column chromatography using silica gel with hexane:EtOAc mixture. The enantiomeric excess values of the products were identified by HPLC analysis on a chiral column using a mixture of *n*-hexane and iso-propanol as the mobile phase.



(2*R*,1'*R*)-2-[Hydroxy-(4-nitro-phenyl)-methyl] cyclohexanone (**8a**): yield: 58% as white solid. Chiralpak OD-H, hexane/*i*-PrOH=95/5, UV 254 nm, flow rate 0.5 ml/min, *syn* product  $t_R$  (major) 56.6 min,  $t_R$ (minor) 66.6 min, ee: 30%, *anti* product  $t_R$  (major) 71.3 min,  $t_R$ (minor) 103.2 min, ee: 47%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.29-8.24 (m, 2H), 7.56-7.50 (m, 2H) 5.53 (d, 1H for *syn*,  $J = 2$  Hz), 4.95 (d, 1H for *anti*,  $J = 8$  Hz), 3.21 (s, 1H), 2.88-1.30 (m, 9H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  214.65 (*anti*), 213.96 (*syn*), 142.25, 139.98, 130.69, 127.89, 126.63, 74.02 (*anti*), 70.15 (*syn*), 57.21 (*anti*), 56.82 (*syn*), 42.68, 40.44, 24.71, 23.77, 23.31 ppm.




(2*R*,1'*R*)-2-[Hydroxy-(3-nitro-phenyl)-methyl] cyclohexanone (**8b**): yield: 52% as white solid. Chiralpak OD-H, hexane/*i*-PrOH=95/5, UV 254 nm, flow rate 0.5 ml/min, *syn* product  $t_R$  (major) 35.9 min,  $t_R$ (minor) 37.5 min, ee: 15%, *anti* product  $t_R$  (major) 42.6 min,  $t_R$ (minor) 61.8 min, ee: 52%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.14-8.02 (m, 2H), 7.61-7.38 (m, 2H), 5.40 (d, 1H for *syn*,  $J = 2$  Hz), 4.83 (d, 1H for *anti*,  $J = 8$  Hz), 3.41 (s, 1H), 2.78-1.26 (m, 9H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  214.82 (*anti*), 214.03 (*syn*), 143.98, 143.37, 132.44, 132.01, 124.39, 123.02, 122.84, 73.99 (*anti*), 65.90 (*syn*), 57.14 (*anti*), 56.78 (*syn*), 30.74, 25.94, 24.75, 24.66 ppm.




(2*R*,1'*R*)-2-[Hydroxy-(2-nitro-phenyl)-methyl] cyclohexanone (**8c**): 46% as pale-yellow solid. Chiralpak OD-H, hexane/*i*-PrOH=95/5, UV 254 nm, flow rate 0.5 ml/min, *syn* product  $t_R$  (minor) 20.3 min,  $t_R$ (major) 23.4 min, ee: 40%, *anti* product  $t_R$  (major)

32.2 min,  $t_R$ (minor) 38.6 min, ee: 67%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.93-7.32 (m, 4H), 5.89 (s, 1H for *syn*), 5.37 (d, 1H for *anti*,  $J = 8$  Hz), 3.27 (s, 1H), 2.82-0.81 (m, 9H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  213.87 (*anti*), 212.91 (*syn*), 147.27, 146.14, 132.12, 132.02, 128.03, 127.92, 127.43, 126.91, 68.72 (*anti*), 65.59 (*syn*), 56.34 (*anti*), 53.86 (*syn*), 41.79, 41.52, 27.67, 26.93, 26.74 ppm.



(2*R*,1'*R*)-2-[Hydroxy-(3-chloro-phenyl)-methyl] cyclohexanone (**8d**): 54% as white solid. Chiralpak OD-H, hexane/*i*-PrOH=95/5, UV 220 nm, flow rate 0.5 ml/min, *syn* product  $t_R$  (minor) 18.1 min,  $t_R$ (major) 19.0 min, ee: 23%, *anti* product  $t_R$  (major) 22.7 min,  $t_R$ (minor) 30.1 min, ee: 18%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.33-7.15 (m, 4H), 5.35 (d, 1H for *syn*,  $J = 2$  Hz), 4.74 (d, 1H for *anti*,  $J = 8$  Hz), 2.60-1.25 (m, 9H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  215.20 (*anti*), 214.46 (*syn*), 143.71, 143.12, 129.86, 129.62, 128.48, 128.39, 128.07, 127.18, 74.30 (*anti*), 70.11 (*syn*), 57.30 (*anti*), 57.00 (*syn*), 30.81, 25.96, 24.73, 23.83, 23.36 ppm.



(2*R*,1'*R*)-2-[Hydroxy-(4-bromo-phenyl)-methyl] cyclohexanone (**8e**): yield: 50% as white solid. Chiralpak OD-H, hexane/*i*-PrOH=90/10, UV 254 nm, flow rate 1 ml/min, *syn* product  $t_R$  (minor) 6.6 min,  $t_R$ (major) 7.8 min, ee: 69%, *anti* product  $t_R$  (major) 9.9 min,  $t_R$ (minor) 13.5 min, ee: 73%.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.57-7.49 (m, 2H), 7.29-7.22 (m, 2H), 5.38 (d, 1H for *syn*,  $J = 4$  Hz), 4.80 (d, 1H for *anti*,  $J = 8$  Hz), 3.23 (s, 1H), 2.86-1.31 (m, 9H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  215.23 (*anti*), 214.52 (*syn*), 140.58, 140.08, 134.53, 134.25, 131.76, 131.51, 128.77, 127.58, 74.21 (*anti*), 70.19 (*syn*), 57.36 (*anti*), 57.02 (*syn*), 42.68, 40.33, 27.94, 26.00, 24.74, 23.83, 23.34 ppm.

Figure S1:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **3**.




Figure S2:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **4**.






Figure S3:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **5a**.





Figure S4:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **5b**.





Figure S5:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **5c**.





Figure S6:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **5d**.




Figure S7:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **6a**.





Figure S8:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **6b**.





Figure S9: HRMS data of **3**.




Figure S10: HRMS data of **4**.




Figure S11: HRMS data of **5a**.




Figure S12: HRMS data of **5b**.




Figure S13: HRMS data of **5c**.




Figure S14: HRMS data of **5d**.




Figure S15: HRMS data of **6a**.




Figure S16: HRMS data of **6b**.






Figure S17:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8a**.





Figure S18:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8b**.




Figure S19:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8c**.





Figure S20:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8d**.




Figure S21:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8e**.




Figure S22:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8f**.




Figure S23:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8g**.





Figure S24:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8h**.







Figure S25:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8i**.





Figure S26:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8j**.




Figure S27:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8k**.




Figure S28:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8l**.





Figure S29:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8m**.





Figure 30:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8n**.





Figure S31:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **8o**.





Figure S32: HPLC data of enantioenriched and racemic of **8a**.







Figure S33: HPLC data of enantioenriched and racemic of **8b**.







Figure S34: HPLC data of enantioenriched and racemic of **8c**.



	Peak Name	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	Peak1	7.443	7245344	92.30	479125	91.44
2	Peak2	8.299	604349	7.70	44873	8.56



	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	7.496	32358794	49.81	1917931	49.18
2	8.293	32601966	50.19	1981868	50.82

Figure S35: HPLC data of enantioenriched and racemic of **8d**.





Figure S36: HPLC data of enantioenriched and racemic of **8e**.





Figure S37: HPLC data of enantioenriched and racemic of **8f**.





Figure S38: HPLC data of enantioenriched and racemic of **8g**.







Figure S39: HPLC data of enantioenriched and racemic of **8h**.



	RT (min)	Area ( $\mu\text{V}\cdot\text{sec}$ )	% Area	Height ( $\mu\text{V}$ )	% Height
1	10.037	4742229	90.31	221594	92.06
2	17.132	508957	9.69	19118	7.94



	Peak Name	RT (min)	Area ( $\mu\text{V}\cdot\text{sec}$ )	% Area	Height ( $\mu\text{V}$ )	% Height
1	Peak1	10.452	34458734	50.00	409111	55.22
2	Peak2	17.459	34461031	50.00	320815	44.78

Figure S40: HPLC data of enantioenriched and racemic of **8i**.







Figure S41: HPLC data of enantioenriched and racemic of **8j**.







Figure S42: HPLC data of enantioenriched and racemic of **8k**.



	RT (min)	Area ( $\mu\text{V}\cdot\text{sec}$ )	% Area	Height ( $\mu\text{V}$ )	% Height
1	36.606	16230359	87.81	232237	91.35
2	40.036	2253740	12.19	21989	8.65



	Peak Name	RT (min)	Area ( $\mu\text{V}\cdot\text{sec}$ )	% Area	Height ( $\mu\text{V}$ )	% Height
1	Peak1	36.678	9271940	51.03	94826	56.37
2	Peak2	43.235	8549610	48.97	70462	43.63

Figure S43: HPLC data of enantioenriched and racemic of **81**.





Figure S44: HPLC data of enantioenriched and racemic of **8m**.





Figure S45: HPLC data of enantioenriched and racemic of **8n**.





Figure S46: HPLC data of enantioenriched and racemic of **80**.





Figure S47:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **9a**.





Figure S48:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **9b**.







Figure S49:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **9c**.




Figure S50:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **9d**.





Figure S51:  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR of **9e**.





Figure S52: HPLC data of enantioenriched and racemic of **9a**.





Figure S53: HPLC data of enantioenriched and racemic of **9b**.





Figure S54: HPLC data of enantioenriched and racemic of **9c**.





Figure S55: HPLC data of enantioenriched and racemic of **9d**.





Figure S56: HPLC data of enantioenriched and racemic of **9e**.

